G Medical Innovations Holdings Ltd · OTC:GMVDF
G Medical Innovations — IPO Roadshow (March 2023)
29 slides from G Medical Innovations's IPO roadshow presentation, Mar 27, 2023
Slide 1: Investor Presentation March 2023
MEDICAL March 2023 INVESTOR PRESENTATION Nasdaq: GMVD Free Writing Prospectus Dated March 27, 2023 Filed pursuant to Rule 433 Relating to Preliminary Prospectus Dated March 24, 2023 Registration Statement on Form F - 1 (No. 333 - 269496)
Slide 2: Forward-Looking Statements
Forward - Looking Statements This presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qua
Slide 3: Offering Summary
Issuer G Medical Innovations Holdings Ltd. Symbol Nasdaq : GMVD Expected Offering Size $12,070,000 Securities Offered Ordinary shares (Or for purchasers whose purchase of Ordinary Shares in this offering would otherwise result in the purchaser beneficially owning more than 4 . 99 % of the outstandin
Slide 4: Company Overview
Company Overview 4 • We develop and market clinical and consumer medical - grade remote monitoring systems focused on chronic diseases as well as develop and market at - home testing kits which will be delivered to and processed by our CLIA certified lab, once operational, which we expect to occur i
Slide 5: Rapidly Rising US Population HealthCare Risk
Rapidly Rising US Population HealthCare Risk https:/ /w w w.cdc.gov/chronicdisease/resources/infographic/chronic - diseases.htm • 900,000 annual deaths due to heart diseases • 183,000 annual deaths related to AFIB • 12M AFIB patients by 2030 • 1 of 2 Americans have high BP (116M) • $147B loss of pro
Slide 6: Rapidly Rising US Healthcare Cost
https:// www.cms.gov/research - statistics - data - and - systems/statistics - trends - and - reports/nationalhealthexpenddata/nhe - fact - sheet Forecasted national health expenditure 2021 - 2028 Rapidly Rising US Healthcare Cost US National Health Expenditure ("NHE") Is Projected To Reach $6.2 Tri
Slide 7: Tele-Health & At-Home Testing – Paradigm Shift
Care givers & payers 1 Tele - Health & At - Home Testing – Paradigm Shift Towards Solving the Problem • At - Home hospitalization cost for acute care episodes is approximately 40 % lower than hospital admission costs for those same episodes . • The At - Home hospitalization model also relieves press
Slide 8: Tele-Health & At-Home Testing – A Strong Reimbursement Incentive
“ Over the last few years, I have witnessed a marked willingness by insurers to reimburse for lower - cost and, in many cases, more effective tele - health & at - home solutions over traditional care. Based on the fundamental shift in the technology against the backdrop of rising costs and an overal
Slide 9: Our Tele-Health Devices and Monitoring Solutions
Our Tele - Health Devices and Monitoring Solutions • Devices share data between patients and doctors • AI based algorithms for real - time alerts • FDA cleared • Patented technologies • Reimbursed by insurers • Scalable manufacturing • Medicare - Certified independent diagnostic testing facilities •
Slide 10: How it Works in a Real-Life Situation
Jeff gets his device delivered to his house Jeff’s doctor prescribes a G Medical device Jeff’s vital information is transmitted to his doctor via the cloud Jeff’s information is continuously monitored at our clinic. Jeff’s insurance carrier approves Jeff (68) suffers from Chronic Heart Disease Our T
Slide 11: How We Measure Up In the Tele-Health Landscape
MEDICAL Real Time Abnormal ECG Detection Remote Call Center Monitoring Long Term Care High Risk Patient Monitoring Vital Signs Monitoring (Not Approved by the FDA) How We Measure Up In the Tele - Health Landscape We believe that we are the only one - stop shop multifunctional platform of devices and
Slide 12: Commercial Agreements and Partnerships
• Three - year agreement with LiveCare, a U.S. - based remote patient monitoring service provider. • LiveCare will integrate G Medical’s Prizma suite of devices into LiveCare’s smart home gateway and offered to direct - to - consumers in the United States. • Agreement with All County Health Care of
Slide 13: The At-Home Testing Kit Market & Our Kit Developments
The At - Home Testing Kit Market & Our Kit Developments • In the second half of 2022, we decided to focus on comprehensive home testing solutions as part of our vision to move towards a home - based healthcare system. • We have developed a wide range of consumer focused At - Home Testing Kits used t
Slide 14: At-Home Testing Kits
1. Thyroid 2. Colon Cancer Screening 3. Indoor/Outdoor Allergy 4. Extensive Fitness 5. Heart Health 6. HbA1c 7. Sleep and Stress 8. Weight Loss 9. Skin Vitality 10. Testosterone 11. Men's Health 12. HPV 13. Women's Health 14. Perimenopause 15. Post menopause 16. Women's Fertility 17. Mother's Milk D
Slide 15: How it Works
How it Works Purchase the home test kit in the online or in a retail store Login to the portal with your username and password Register your kit Perform the test Send test sample to the lab in pre - paid shipping bag Get results online in days 15
Slide 16: Sales Consulting Agreement with Ideaology
Sales Consulting Agreement with Ideaology 360 • Ideaology 360 has accumulated extensive experience & relationships in marketing health and wellness products. • Ideaology 360’s client’s products have achieved sales in excess of $1 billion in the US retail market. • Retail sales network currently repr
Slide 17: At-Home Testing Kit Comparable Company
Everlywell is a direct - to - consumer health testing company that connects people with accessible, innovative, and insightful at - home lab tests . 1 Everlywell, whose founder appeared on entrepreneur - oriented television show “Shark Tank,” announced a financing round in 2020 that valued the compa
Slide 18: Management Team
Management Team Dr . Yacov Geva, CEO, Executive Director A well - known pioneer in the industry of Medical Devices and remote monitoring services, and co - founder of LifeWatch AG (former Card Guard AG and Card Guard Scientific Survival Ltd . ) . Successfully led LifeWatch to an IPO . Dr . Geva hold
Slide 19: Board Members
Dr . Kenneth R . Melani Non - Executive Chairman, began his career in 1981 as a practicing physician growing his internal medicine practice into the largest multi - specialty physician practice in Western Pennsylvania . In the mid 1980 ’s he helped start a physician hospital organization, West Penn
Slide 20: Financial Summary
Financial Summary Summary Operations Data U.S. dollars in thousands For the year ended December 31 For the six months ended June 30 2021 2020 2022 2021 Total Revenue $5,058 $4,900 $2,224 $2,925 Total Cost of Revenue $3,556 $4,233 $7,141 $1,784 Gross Profit (loss) $1,502 $667 1 $(4,917) $1,141 Operat
Slide 21: Summary Balance Sheet and Cap Table
Summary Balance Sheet and Cap Table 21 1. As adjusted data gives effect to the repayment of the April 2021 Financing Debentures ($600,000 principal plus accrued interest), and the issuance and sale of Ordinary Shares in this offering, at an assumed public offering price of $1.70 per share, which is
Slide 22: Investment Highlights
Investment Highlights • FDA cleared tele - health devices with CPT code reimbursement approval at more than 150 leading health insurance providers in the US. • CMS approved independent diagnostic testing facilities. • Commercial agreements in place for the marketing, sale and distribution of our Pri
Slide 23: Appendix
MEDICAL Appendix 23
Slide 24: Management Team Cont.
24 MANAGEMENT TEAM CONT. Tim Lohman, VP Operation G Medical Diagnostic Mr . Lohman has served in various roles in the healthcare industry for 40 years, specifically in remote diagnostic services . Lohman received his technical background as a biomedical equipment specialist in the U . S . Army and N
Slide 25: Intellectual Property
25 INTELECTUAL PROPERTY A wide and strong patent l ist t hat protect o ur pro ucts and s ervices Patent Name Country Status Patent Number/ Application Number Product d Type of Protection Expiration date SYSTEMS AND METHODS FOR VITAL SIGNS MONITORING WITH EARPIECE United states Granted 10251603 VSMS
Slide 26: Web Portal for Patients and Physicians
WEB PORTAL FOR PATIENTS AND PHYSICIANS Top Menu help and 3rd party systems like CRM, Call Center and Online Store Patients' medical history with option to edit and view for comprehensive status Abnormal measurements indication based on flexible time filter Incoming calls and history supporting a tri
Slide 27: Growth of AFib Prevalence in the USA
https ://w ww .reve s pcardiol.org/en - atrial - fibrillation - is - it - an - articulo - 13131641 27 GROWTH OF AFIB PREVALENCE IN THE USA
Slide 28: Prevalence of AFib Will Only Increase in the Future
1. Williams BA, et al. JAMA Network Open. 2020. 2. Blue Cross Blue Shield, 2018 (bcbs.com) PREVALENCE OF AFIB WILL ONLY INCREASE IN THE FUTURE WITH AGING POPULATION AND LIFESTYLE RELATED COMORBIDITY AFIB incidence rapidly rising (2006 - 2018) 1 Millennials are less healthy than 2 age matched Gen Xer
Slide 29: Identifying and Treating AFib Early Is Critical
Early rhythm - control therapy associated with a lower risk of adverse cardiovascular outcomes 29 Incidence of death from cardiovascular causes, stroke, or hospitalization reduced with early rhythm control Death or hospitalization for worsening heart failure reduced with catheter ablation for AFib 1
G Medical Innovations Holdings — IPO Roadshow (March 2023) on 6ix